dose range raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-16 and is reviewed periodically as new material appears.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
In November 1993, relator Robert Marena, an SKB employee, filed a qui tam action against GlaxoSmithKline in the United States District Court for the Eastern District of Pennsylvania. His complaint contained eight separate claims under the False Claims Act. Merena's complaint alleged that SKB had defrauded the government by, inter alia, billing for tests that were not performed, double billing, paying illegal kickbacks to health care professionals, and adding tests to "automated chemistry" profiles and then separately billing for those tests. After a month, relator Glenn Grossenbacher, an attorney, filed a second qui tam action against GlaxoSmithKline in the United States District Court for the Western District of Texas. Relators Kevin Spear, Jack Dowden, and the Berkeley Community Law Center (collectively, "the Spear relators") followed in February 1995 with a suit in the Northern District of California. The courts in Texas and California transferred these actions to the Eastern District of Pennsylvania for consolidation with the Merena case. After Merena's action was filed, the government commenced an investigation into a series of new claims that were not part of its original investigation. At the same time, the government continued to pursue the original "automated chemistry" investigation that it had begun after the 1992 settlement with National Health Laboratories. Later in August 1995, the government began formal settlement negotiations with GlaxoSmithKline.
The problem of minimizing ET is an NP-hard problem. Even though the class of problems is NP-hard, in practice many instances of protein design can be solved exactly or optimized satisfactorily through heuristic methods.
In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that product labels for all SSRIs and SNRIs, including sertraline, be updated to state that sexual dysfunction may be long-lasting even after treatment is stopped. Health Canada followed with similar label updates in 2021. In 2024, Australia's Therapeutic Goods Administration aligned all SSRI and SNRI product information to reflect this risk, noting that sertraline already carried a warning about persistent sexual dysfunction.
In October 2010, Biden said Obama had asked him to remain as his running mate for the 2012 presidential election, but with Obama's popularity declining, White House Chief of Staff William M. Daley conducted some secret polling and focus group research in late 2011 on the idea of replacing Biden with Hillary Clinton. The notion was dropped when the results showed no appreciable improvement, and White House officials later said Obama himself never entertained the idea. Biden's May 2012 statement that he was "absolutely comfortable" with same-sex marriage gained considerable public attention in comparison to Obama's position, which had been described as "evolving". Biden made his statement without administration consent, and Obama and his aides were irked, since Obama had planned to shift position in the build-up to the party convention. Gay rights advocates seized upon Biden's statement, and within days, Obama announced that he too supported same-sex marriage, an action in part forced by Biden's remarks. Biden had a heavy schedule of appearances in swing states as the reelection campaign began in earnest in spring 2012. An August 2012 remark before a mixed-race audience that Republican proposals to relax Wall Street regulations would "put y'all back in chains" again drew attention to Biden's propensity for colorful remarks.
In the eastern United States in the early 2000s, sulfate particles were estimated to account for 25% or more of all air pollution. Exposure to sulfur dioxide emissions by coal power plants (coal PM2.5) in the US was associated with 2.1 times greater mortality risk than exposure to PM2.5 from all sources. Meanwhile, the Southern Hemisphere had much lower concentrations due to being much less densely populated, with an estimated 90% of the human population in the north. In the early 1990s, anthropogenic sulfur dominated in the Northern Hemisphere, where only 16% of annual sulfur emissions were natural, yet amounted for less than half of the emissions in the Southern Hemisphere.
Sources: en.wikipedia.org
== External links == MedEd at Loyola grossanatomy/dissector/labs/h_n/pharynx/ph2_1a.html lesson8 at The Anatomy Lesson by Wesley Norman (Georgetown University) (latpharyngealitmes) MedicalMnemonics.com: 669 Cross section at tufts.edu
=== High-throughput synthesis === High-throughput (HT) methods are a part of combinatorial chemistry and a tool for increasing efficiency. There are two synthetic strategies within the HT-methods: In the combinatorial approach, all reactions take place in one vessel, which leads to product mixtures. In the parallel synthesis, the reactions take place in different vessels. Furthermore, a distinction is made between thin films and solvent-based methods. Solvothermal synthesis can be carried out conventionally in a teflon reactor in a convection oven or in glass reactors in a microwave oven (high-throughput microwave synthesis). The use of a microwave oven changes, in part dramatically, the reaction parameters. In addition to solvothermal synthesis, there have been advances in using supercritical fluid as a solvent in a continuous flow reactor. Supercritical water was first used in 2012 to synthesize copper and nickel-based MOFs in just seconds. In 2020, supercritical carbon dioxide was used in a continuous flow reactor along the same time scale as the supercritical water-based method, but the lower critical point of carbon dioxide allowed for the synthesis of the zirconium-based MOF UiO-66.
After absorbing the Lodges around Havana and some other parts of the island, GOCA was recognized as regular and correct by the Supreme Councils of France, England, Scotland, and some other European countries. According to some Masonic historians, however, Cuba and the Antiles was considered illegal. From 1862 to 1868 GOCA established roughly twenty Lodges around the country. de Castro had no luck in absorbing any of the Lodges around Santiago de Cuba, and they remained loyal to the Grand Orient of Colon. Eastern and Western Cuba became increasingly bifurcated in Freemasonry. Despite being the birthplace of Cuban Freemasonry, Oriente Province, and especially Santiago de Cuba, were considered culturally and geographically isolated to the Lodges around Havana. Andrés Cassard and Albert Pike became furious with de Castro. Pike wrote a letter dated November 17, 1865, and accused GOCA of insubordination. He called it "...nothing more than a putrid den of Jacobins." Pike lamented that GOCA was a club more concerned with politics, and not one that upheld the ideals of Freemasonry. In direct opposition to Pike, GOCA published content in which stated that the Southern Jurisdiction was stuck in the dark ages of Old-Testament mysticism. They argued that instead of the Anglo-American motto of Freemasonry, theirs was more closely aligned with the original French Masonic tradition that had once existed in Cuba: Liberty, Equality, Fraternity. They espoused liberalism, declared themselves to be rationalist and Enlightenment thinkers, democratic and anticlerical.
== Epidemiology == Approximately 34% of people with diabetes (Type 1 or Type 2 diabetes) will develop a foot ulcer in their lifetime. 18.6 million people worldwide will develop a foot ulcer each year. 15-20% of moderately to severely infected foot ulcers eventually lead to amputation, and the mortality rate of diabetic foot ulcers is 30% at 5 years with a mortality rate of 70% in those with a foot ulcer who receive an above the foot amputation. Foot ulcers and amputations are associated with a reduced quality of life. In the United States, Black people, Native Americans, Hispanics, and those living in rural areas or those with a lower socioeconomic status have an increased rate of amputations due to diabetic foot ulcers. Approximately 8.8 percent of hospital admissions of diabetic patients are for foot-related problems, and such hospital admissions are about 13 days longer than for diabetics without foot-related admissions. Approximately 58% of ulcers recur within 3 years and up to 65% recur within 5 years, sometimes at a different location that the original ulcer. Diabetic foot disease is the leading cause of non-traumatic lower limb amputations.
== Early years == Early on, Pultronics delved in the field of optoelectronics. It explored how optoelectronic techniques can be used in the testing of integrated circuits (ICs). Other optoelectronics research focused on optical distribution systems and on how packaging affects optical transmissions.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.